Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807781 · ClinicalTrials.gov registry record · Phase 1
Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00807781 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT00807781, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of mammaglobin-A DNA vaccine in metastatic breast cancer patients.
Interventions
- BIOLOGICAL Mammaglobin-A DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807781
The ClinicalTrials.gov registry entry for NCT00807781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mammaglobin-A DNA vaccine is the first listed.
NCT00807781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807781 about?
NCT00807781 is a clinical study titled "Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer". The purpose of this study is to evaluate the safety of mammaglobin-A DNA vaccine in metastatic breast cancer patients.
What is the current status of trial NCT00807781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00807781?
The interventions under investigation include: Mammaglobin-A DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00807781?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.